Neptune Technologies (NEPT) Obtains Krill Oil Patent, Makes Management Changes
Tweet
Share
E-mailGet Alerts NEPT Hot Sheet
Join SI Premium – FREE
Neptune Technologies & Bioressources Inc. (Nasdaq: NEPT ) announces that the U.S. Patent & Trademark Office has allowed a second continuation patent application, application number 13/545,830, which claims the benefit of prior Neptune U.S. Patents No. 8,030,348 ("the '348 Patent") and 8,278,351 ("the '351 Patent").
This second continuation application contains only a single claim, which is directed to a capsule comprising an Antarctic krill oil extract comprising a phospholipid suitable for human consumption. This claim covers most, if not all, krill oil products presently sold in the U.S. market.
This second continuation application, which was filed less than six (6) months ago, was allowed by the USPTO after a thorough examination. During prosecution, Neptune provided the USPTO with all prior art references and other materials, including all the documents referred to in all of the re-examination requests filed by Aker Biomarine ASA ("Aker") directed to the '348 and '351 Patents, as well as all the documents relating to the oppositions currently underway on related Neptune patents in Europe and Australia.
Management Reorganization
Neptune also announces that, effective January 23, 2013, Henri Harland, President and Chief Executive Officer of Neptune, will cumulate for an interim period of time, during the implementation of Neptune's plan to resume production, the functions and responsibilities held previously by Michel Chartrand, as Chief Operating Officer, who will continue to hold office as member of the Board of Director. "Michel and I came to the conclusion that until Neptune resumes operations at its production plant; it was in Neptune's best interest to abolish the office of Chief Operating Officer for an interim period of time. We believe that Michel will better serve Neptune's interests by focusing on his responsibilities as Director of the company during his mandate," said Henri Harland.
This second continuation application contains only a single claim, which is directed to a capsule comprising an Antarctic krill oil extract comprising a phospholipid suitable for human consumption. This claim covers most, if not all, krill oil products presently sold in the U.S. market.
This second continuation application, which was filed less than six (6) months ago, was allowed by the USPTO after a thorough examination. During prosecution, Neptune provided the USPTO with all prior art references and other materials, including all the documents referred to in all of the re-examination requests filed by Aker Biomarine ASA ("Aker") directed to the '348 and '351 Patents, as well as all the documents relating to the oppositions currently underway on related Neptune patents in Europe and Australia.
Management Reorganization
Neptune also announces that, effective January 23, 2013, Henri Harland, President and Chief Executive Officer of Neptune, will cumulate for an interim period of time, during the implementation of Neptune's plan to resume production, the functions and responsibilities held previously by Michel Chartrand, as Chief Operating Officer, who will continue to hold office as member of the Board of Director. "Michel and I came to the conclusion that until Neptune resumes operations at its production plant; it was in Neptune's best interest to abolish the office of Chief Operating Officer for an interim period of time. We believe that Michel will better serve Neptune's interests by focusing on his responsibilities as Director of the company during his mandate," said Henri Harland.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intrepid Potash (IPI) Grants CEO Temporary Medical Leave of Abscence
- NeoGenomics (NEO) Announces Senior Leadership Promotions
- Phoenix Motor Inc (PEV) Appoints Michael Yung as CFO
Create E-mail Alert Related Categories
Corporate News, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
